6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrimidin-4-amine | 404829-31-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrimidin-4-amine
• CAS: 404829-31-8
• 化学式: C₁₄H₁₂ClN₅
• 分子量: 285.736
• InChiKey: ZYSRCGLTFICAEO-UHFFFAOYSA-N

物化性质

• 沸点：
  419.8±45.0 °C(Predicted)
• 密度：
  1.380±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-甲基-1-哌嗪乙胺 、 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrimidin-4-amine 在 水 、 silica gel 作用下， 反应 8.0h， 以to afford N4-(5-methyl-1H-pyrazol-3-yl)-N6-(2-(4-methylpiperazin-1-yl)ethyl)-2-phenylpyrimidine-4,6-diamine (14 mg, 9%) as an off white solid的产率得到N4-(5-methyl-1H-pyrazol-3-yl)-N6-(2-(4-methylpiperazin-1-yl)ethyl)-2-phenylpyrimidine-4,6-diamine
  参考文献：
  名称：

  SUBSTITUTED PYRAZOLE COMPOUNDS

  摘要：

  本发明涉及蛋白激酶抑制剂、包含这些抑制剂的组合物以及使用它们的方法。更具体地，本发明涉及Aurora A（Aurora-2）蛋白激酶的抑制剂。本发明还涉及治疗与蛋白激酶相关的疾病的方法，特别是与Aurora-2相关的疾病，如癌症。

  公开号：

  US20090029992A1
• 作为产物：
  描述：

  解草啶 、 3-氨基-5-甲基吡唑 、 N,N-二异丙基乙胺 、 碘化钠 在 crude product 、 silica gel 、 Petrol 、 乙酸乙酯 作用下， 以 正丁醇 为溶剂， 反应 18.0h， 以to afford 0.037 g (29% yield) of (6-Chloro-2-phenyl-pyrimidin-4-yl)-(5-methyl-2H-pyrazol-3-yl)-amine as a off-white solid的产率得到6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenylpyrimidin-4-amine
  参考文献：
  名称：

  Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors

  摘要：

  本发明描述了式IV的新型吡唑化合物：其中环D是选择自芳基、杂芳基、杂环芳基或碳环芳基的5-7成员单环或8-10成员双环；Rx和Ry独立地选择自T-R3，或者与它们之间的原子相互结合形成融合的、不饱和的或部分不饱和的、具有1-3个环杂原子（选自氧、硫或氮）的5-8成员环；R2、R2'、T和R3如规范中所述。这些化合物可用作蛋白激酶抑制剂，特别是用作aurora-2和GSK-3的抑制剂，用于治疗癌症、糖尿病和阿尔茨海默病等疾病。

  公开号：

  US08524720B2

文献信息

• Pyrazole compounds useful as protein kinase inhibitors
  申请人：——

  公开号：US20040224944A1

  公开（公告）日：2004-11-11

  This invention describes novel pyrazole compounds of formula IV: 1 wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R 2 , R 2′ , T, and R 3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了公式IV：1的新型吡唑化合物，其中环D是从芳基，杂芳基，杂环基或碳环基中选择的5-7成员单环或8-10成员双环。 Rx和Ry独立选择自T-R3，或者与它们之间的原子结合形成融合的，不饱和的或部分不饱和的5-8成员环，其中有1-3个环杂原子，所述的杂原子选择自氧，硫或氮。 R2，R2'，T和R3如说明书所述。这些化合物可用作蛋白激酶抑制剂，特别是作为aurora-2和GSK-3的抑制剂，用于治疗癌症，糖尿病和阿尔茨海默病等疾病。
• METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS
  申请人：Xiao Xiao-Yi

  公开号：US20090264422A1

  公开（公告）日：2009-10-22

  Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

  本发明涉及蛋白激酶抑制剂、包含此类抑制剂的组合物以及其使用方法。更具体地，披露了Aurora A（Aurora-2）蛋白激酶的抑制剂。还公开了治疗与蛋白激酶相关的疾病，特别是与Aurora-2相关的疾病（如癌症）的方法。
• TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Bebbington David

  公开号：US20120071657A1

  公开（公告）日：2012-03-22

  This invention describes novel triazole compounds of formula IX: wherein Z 1 is nitrogen or CR 9 and Z 2 is nitrogen or CH, provided that at least one of Z 1 and Z 2 is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from —R 1 ; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or R x and R y are taken together with their intervening atoms to form a fused ring; R 1 , R 3 , and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.

  该发明描述了式IX的新型三唑类化合物：其中Z1是氮或CR9，Z2是氮或CH，但至少其中一个为氮；G是环C或环D；环C选自苯基、吡啶基、嘧啶基、吡嗪基、吡咯基或1,2,4-三嗪基环，其中所述的环C具有一个或两个独立选择自-R1的邻位取代基；环D是选自芳基、杂芳基、杂环基或碳环基的5-7成员单环或8-10成员双环环；Rx和Ry独立选择自T-R3，或Rx和Ry与它们之间的原子结合形成螺合环；R1、R3和T如说明书所述。该化合物可用作蛋白激酶抑制剂，特别是GSK-3和Aurora的抑制剂，用于治疗糖尿病、癌症和阿尔茨海默病等疾病。
• PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：Bebbington David

  公开号：US20100256170A1

  公开（公告）日：2010-10-07

  This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R x and R y are independently selected from T-R 3 , or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R 2 , R 2′ , T, and R 3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了式IV的新型吡唑化合物：其中环D为5-7成员单环或8-10成员双环，选自芳基，杂芳基，杂环基或碳环基；Rx和Ry分别选自T-R3，或与其之间的原子结合形成融合的、不饱和或部分不饱和的5-8成员环，其中有1-3个选自氧、硫或氮的环杂原子；R2、R2'、T和R3如说明书所述。这些化合物可用作蛋白激酶抑制剂，特别是aurora-2和GSK-3的抑制剂，用于治疗癌症、糖尿病和阿尔茨海默病等疾病。
• Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors
  申请人：Bebbington David

  公开号：US08524720B2

  公开（公告）日：2013-09-03

  This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2′, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

  本发明描述了式IV的新型吡唑化合物：其中环D是选择自芳基、杂芳基、杂环芳基或碳环芳基的5-7成员单环或8-10成员双环；Rx和Ry独立地选择自T-R3，或者与它们之间的原子相互结合形成融合的、不饱和的或部分不饱和的、具有1-3个环杂原子（选自氧、硫或氮）的5-8成员环；R2、R2'、T和R3如规范中所述。这些化合物可用作蛋白激酶抑制剂，特别是用作aurora-2和GSK-3的抑制剂，用于治疗癌症、糖尿病和阿尔茨海默病等疾病。